Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + thioguanine + cyclophosphamide + busulfan + melphalan
- Development stage
- Unknown
- Lead developer
- Dutch Childhood Oncology Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This intensive multi-agent chemotherapy combination consists of etoposide, thioguanine, cyclophosphamide, busulfan, and melphalan. It was evaluated by the Dutch Childhood Oncology Group (DCOG) as a conditioning or intensive re-induction regimen for pediatric and adolescent patients with relapsed or refractory acute myeloid leukemia (AML). The regimen leverages multiple cytotoxic pathways: etoposide inhibits DNA topoisomerase II; thioguanine acts as a purine antimetabolite; and cyclophosphamide, busulfan, and melphalan serve as potent DNA alkylating agents. This combination is designed to overcome multi-drug resistance in aggressive myeloid leukemias, often serving as a bridge to hematopoietic stem cell transplantation.
- Other names
- etoposide + thioguanine + cyclophosphamide + busulfan + melphalan-Dutch Childhood Oncology Group-acute myeloid leukemiaEtoposide/Thioguanine/Cyclophosphamide/Busulfan/Melphalan
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on etoposide + thioguanine + cyclophosphamide + busulfan + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + thioguanine + cyclophosphamide + busulfan + melphalan.